Form 4 for GNLX GENELUX Corp
Accepted 2023-10-25 00:00:00 ET · period of report 2023-10-24 · accession 0001209191-23-053554 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-25 | 2023-10-24 | GNLX | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $19.11 | -5,200 | 106.1K | -5% | -$99.4K |
| D | 2023-10-25 | 2023-10-24 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +5,200 | 111.3K | +5% | +$31.2K |
| D | 2023-10-25 | 2023-10-24 | GNLX | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $0.00 | -5,200 | 207.7K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-24 | S | D | 5,200 | $19.11 | 106,135 | D | — | — | (F2) The weighted average sale price for the transaction reported was $19.106, and the range of prices were between $19.00 and $19.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. |
| 2 | Common | Common Stock | 2023-10-24 | M | A | 5,200 | $6.00 | 111,335 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2023-10-24 | M | D | 5,200 | $0.00 | 207,653 | D | $6.00 · — to 2029-09-20 | 5,200 Common Stock | (F3) Immediately exercisable. |